Skip to main content
. 2018 May 22;38(3):BSR20170100. doi: 10.1042/BSR20170100

Table 1. Distribution of CREB3L1- and PTN-positive people.

Number (%)
CREB3L1+ PTN+
Control (n=9) 9 (100) 1 (11)
Low-grade (n=17) 13 (76)* 14 (82)*
High-grade (n=25) 10 (40)† 25 (100)†
*

P<0.05 compared with the control; †P<0.05 compared with either the control or the low-grade glioma.